LONDON(The COW News Digital) Advanced clinical trials reveal that next-generation experimental weight-loss treatments could prove significantly more effective than existing leading medications like Mounjaro, delivering unprecedented body weight reduction in shorter treatment windows.
Comparative data indicates that Tirzepatide, the active ingredient in Mounjaro, helps patients lose an average of 19% of their overall body weight over approximately 17 months. In contrast, trials evaluating the experimental compound Retatrutide showed participants achieving an average weight reduction of 22.1% in just 48 weeks. Another novel candidate, Amycretin, yielded even higher efficacy, with clinical trial subjects losing nearly 23.9% of their body mass within a 36-week trial period.
These new findings also surpass outcomes recorded for widely used Semaglutide-based injections such as Wegovy and Ozempic, which typically produce an average weight loss of around 18% over comparable durations.
Despite these promising clinical trial metrics, medical experts emphasize that neither Retatrutide nor Amycretin has yet received formal regulatory approval from health authorities, including the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). Researchers stress that extensive further clinical testing and safety evaluations remain essential before these experimental therapies can achieve regulatory clearance and widespread public availability.
